MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, today announced its plan to reduce the size of its Board of Directors following its 2026 Annual Meeting of Stockholders on May 21, 2026. Stanley M. Bergman is to retire from the Board after 44 years as a director of Henry Schein. In recognition of Mr. Bergman's leadership and the significant contributions he has made to the Co.

Ari Sass of the M.D. Sass Concentrated Value ETF is hunting for reasonably priced growth stocks like Henry Schein.

Shares of Henry Schein, Inc. (NASDAQ: HSIC - Get Free Report) have received a consensus recommendation of "Hold" from the thirteen brokerages that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and six have assigned a buy rating to

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock?

HSIC's growth from its Henry Schein One venture and partnerships is promising, but macro pressures and stiff competition raise concerns for investors.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, has been recognized as one of the 2026 World's Most Ethical Companies® by Ethisphere, a global leader in defining and advancing the standards of ethical business practices. “To be honored for our ethical practices reflects the values that have guided Henry Schein for decades,” said Fred M. Lowery, Chief Executive Officer of He.

Cooper Companies (NASDAQ: COO - Get Free Report) and Henry Schein (NASDAQ: HSIC - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership. Earnings and Valuation This table compares Cooper Companies

Henry Schein, Inc. is rated a 'Buy' as signs of improving growth and undervaluation emerge despite recent stagnation. HSIC's recent results show solid revenue and EPS growth, but operating margins and ROIC remain pressured, challenging its economic moat. Management guides for 3–5% sales growth and 5–8% non-GAAP EPS growth in 2026, supported by strategic focus on high-margin businesses and digital transformation.